{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:08:31Z","timestamp":1793210911732,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"16","license":[{"start":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T00:00:00Z","timestamp":1570665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T00:00:00Z","timestamp":1570665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s40265-019-01210-0","type":"journal-article","created":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T13:09:39Z","timestamp":1570712979000},"page":"1805-1812","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":229,"title":["Pexidartinib: First Approval"],"prefix":"10.1007","volume":"79","author":[{"given":"Yvette N.","family":"Lamb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,10]]},"reference":[{"issue":"8","key":"1210_CR1","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1158\/1535-7163.MCT-16-0866","volume":"16","author":"JY Ao","year":"2017","unstructured":"Ao JY, Zhu XD, Chai ZT, et al. Colony-stimulating factor 1 receptor blockade inhibits tumor growth by altering the polarization of tumor-associated macrophages in hepatocellular carcinoma. Mol Cancer Ther. 2017;16(8):1544\u201354.","journal-title":"Mol Cancer Ther."},{"issue":"1","key":"1210_CR2","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8274.CD-10-0028","volume":"1","author":"DG DeNardo","year":"2011","unstructured":"DeNardo DG, Brennan DJ, Rexhepaj E, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011;1(1):54\u201367.","journal-title":"Cancer Discov."},{"issue":"5","key":"1210_CR3","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1056\/NEJMoa1411366","volume":"373","author":"WD Tap","year":"2015","unstructured":"Tap WD, Wainberg ZA, Anthony SP, et al. Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor. N Engl J Med. 2015;373(5):428\u201337.","journal-title":"N Engl J Med."},{"issue":"1","key":"1210_CR4","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ymthe.2018.11.010","volume":"27","author":"G Shi","year":"2019","unstructured":"Shi G, Yang Q, Zhang Y, et al. Modulating the tumor microenvironment via oncolytic viruses and CSF-1R inhibition synergistically enhances anti-PD-1 immunotherapy. Mol Ther. 2019;27(1):244\u201360.","journal-title":"Mol Ther."},{"issue":"6","key":"1210_CR5","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1093\/neuonc\/nov272","volume":"18","author":"JH Stafford","year":"2016","unstructured":"Stafford JH, Hirai T, Deng L, et al. Colony stimulating factor 1 receptor inhibition delays recurrence of glioblastoma after radiation by altering myeloid cell recruitment and polarization. Neuro Oncol. 2016;18(6):797\u2013806.","journal-title":"Neuro Oncol."},{"key":"1210_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1758835919854238","volume":"11","author":"R Wesolowski","year":"2019","unstructured":"Wesolowski R, Sharma N, Reebel L, et al. Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors. Ther Adv Med Oncol. 2019;11:1\u201313.","journal-title":"Ther Adv Med Oncol."},{"key":"1210_CR7","doi-asserted-by":"publisher","first-page":"3632","DOI":"10.1182\/blood.V118.21.3632.3632","volume":"118","author":"E Burton","year":"2011","unstructured":"Burton E, Wong B, Zhang J. The novel inhibitor PLX3397 effectively inhibits FLT3-mutant AML. Blood. 2011;118:3632.","journal-title":"Blood."},{"issue":"6","key":"1210_CR8","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1158\/2159-8290.CD-15-0060","volume":"5","author":"CC Smith","year":"2015","unstructured":"Smith CC, Zhang C, Lin KC, et al. Characterizing and overriding the structural mechanism of the quizartinib-resistant FLT3 \u201cgatekeeper\u201d F691L mutation with PLX3397. Cancer Discov. 2015;5(6):668\u201379.","journal-title":"Cancer Discov."},{"key":"1210_CR9","unstructured":"Daiichi Sankyo Inc. TURALIOTM (pexidartinib) capsules, for oral use: US prescribing information 2019. \nhttp:\/\/www.accessdata.fda.gov\/\n\n. Accessed 30 Sep 2019."},{"issue":"4","key":"1210_CR10","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.clinthera.2016.03.008","volume":"38","author":"HL Gelhorn","year":"2016","unstructured":"Gelhorn HL, Tong S, McQuarrie K, et al. Patient-reported symptoms of tenosynovial giant cell tumors. Clin Ther. 2016;38(4):778\u201393.","journal-title":"Clin Ther."},{"key":"1210_CR11","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13569-018-0101-2","volume":"8","author":"N Giustini","year":"2018","unstructured":"Giustini N, Bernthal NM, Bukata SV, et al. Tenosynovial giant cell tumor: case report of a patient effectively treated with pexidartinib (PLX3397) and review of the literature. Clin Sarcoma Res. 2018;8:14.","journal-title":"Clin Sarcoma Res."},{"key":"1210_CR12","unstructured":"Food and Drug Administration. FDA approves first therapy for rare joint tumor [media release]. 2 Aug 2019. \nhttp:\/\/www.fda.gov\n\n."},{"issue":"10197","key":"1210_CR13","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/S0140-6736(19)30764-0","volume":"394","author":"WD Tap","year":"2019","unstructured":"Tap WD, Gelderblom H, Palmerini E, et al. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. Lancet. 2019;394(10197):478\u201387.","journal-title":"Lancet."},{"issue":"43","key":"1210_CR14","doi-asserted-by":"publisher","first-page":"6049","DOI":"10.1038\/onc.2017.261","volume":"36","author":"D Yan","year":"2017","unstructured":"Yan D, Kowal J, Akkari L, et al. Inhibition of colony stimulating factor-1 receptor abrogates microenvironment-mediated therapeutic resistance in gliomas. Oncogene. 2017;36(43):6049\u201358.","journal-title":"Oncogene."},{"issue":"12","key":"1210_CR15","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1158\/1078-0432.CCR-13-2576","volume":"20","author":"PP Patwardhan","year":"2014","unstructured":"Patwardhan PP, Surriga O, Beckman MJ, et al. Sustained inhibition of receptor tyrosine kinases and macrophage depletion by PLX3397 and rapamycin as a potential new approach for the treatment of MPNSTs. Clin Cancer Res. 2014;20(12):3146\u201358.","journal-title":"Clin Cancer Res."},{"issue":"1","key":"1210_CR16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1158\/0008-5472.CAN-13-1816","volume":"74","author":"S Mok","year":"2014","unstructured":"Mok S, Koya RC, Tsui C, et al. Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy. Cancer Res. 2014;74(1):153\u201361.","journal-title":"Cancer Res."},{"issue":"Suppl S1","key":"1210_CR17","first-page":"S54","volume":"103","author":"AG Vandell","year":"2018","unstructured":"Vandell AG, Duchin KL, Desai M, et al. Effect of dose strength, food, and pH modifiers on the pharmacokinetics of the multi-kinase inhibitor pexidartinib [abstract no. PI-152]. Clin Pharmacol Ther. 2018;103(Suppl S1):S54.","journal-title":"Clin Pharmacol Ther"},{"key":"1210_CR18","unstructured":"Daiichi Sankyo Inc. Briefing document for the May 14, 2019, US FDA oncologic drugs advisory committee meeting: Turalio (pexidartinib) capsules. 2019. \nhttp:\/\/www.fda.gov\/\n\n. Accessed 30 Sep 2019."},{"issue":"Suppl 15","key":"1210_CR19","doi-asserted-by":"crossref","first-page":"11042","DOI":"10.1200\/JCO.2019.37.15_suppl.11042","volume":"37","author":"H Gelderblom","year":"2019","unstructured":"Gelderblom H, Tap WD, Palmerini E, et al. Pexidartinib for advanced tenosynovial giant cell tumor (TGCT): long-term efficacy and safety from the phase 3 ENLIVEN and phase 1 PLX108-01 (TGCT cohort) studies [abstract no. 11042]. J Clin Oncol. 2019;37(Suppl 15):11042.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1210_CR20","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/neuonc\/nov245","volume":"18","author":"N Butowski","year":"2016","unstructured":"Butowski N, Colman H, De Groot JF, et al. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro Oncol. 2016;18(4):557\u201364.","journal-title":"Neuro Oncol."},{"issue":"Suppl 15","key":"1210_CR21","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1200\/JCO.2018.36.15_suppl.2015","volume":"36","author":"H Colman","year":"2018","unstructured":"Colman H, Raizer JJ, Walbert T, et al. Phase 1b\/2 study of pexidartinib (PEX) in combination with radiation therapy (XRT) and temozolomide (TMZ) in newly diagnosed glioblastoma [abstract no. 2015]. J Clin Oncol. 2018;36(Suppl 15):2015.","journal-title":"J Clin Oncol"},{"issue":"Suppl 15","key":"1210_CR22","doi-asserted-by":"crossref","first-page":"11055","DOI":"10.1200\/JCO.2019.37.15_suppl.11055","volume":"37","author":"GA Manji","year":"2019","unstructured":"Manji GA, Van Tine BA, Lee SM, et al. Phase 1 combination therapy with pexidartinib (PEX) and sirolimus (S) to target tumor-associated macrophages in pigmented villonodular synovitis, malignant peripheral nerve sheath tumors, and other soft tissue sarcomas [abstract no. 11055]. J Clin Oncol. 2019;37(Suppl 15):11055.","journal-title":"J Clin Oncol"},{"key":"1210_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1634\/theoncologist.2019-0418","volume":"24","author":"E Rosenbaum","year":"2019","unstructured":"Rosenbaum E, Kelly C, D\u2019Angelo SP, et al. A phase I study of binimetinib (MEK162) combined with pexidartinib (PLX3397) in patients with advanced gastrointestinal stromal tumor. Oncologist. 2019;24:1\u20138.","journal-title":"Oncologist."},{"issue":"Suppl 15","key":"1210_CR24","doi-asserted-by":"publisher","first-page":"11509","DOI":"10.1200\/JCO.2018.36.15_suppl.11509","volume":"36","author":"AJ Wagner","year":"2018","unstructured":"Wagner AJ, Tap WD, Shields AF, et al. A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of PLX9486 alone and in combination (combo) with the KIT inhibitors pexidartinib (pexi) or sunitinib (su) in patients (Pts) with advanced solid tumors and gastrointestinal stromal tumor (GIST) [abstract no. 11509]. J Clin Oncol. 2018;36(Suppl 15):11509.","journal-title":"J Clin Oncol"},{"issue":"Suppl 15","key":"1210_CR25","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1200\/JCO.2019.37.15_suppl.2579","volume":"37","author":"PA Cassier","year":"2019","unstructured":"Cassier PA, Garin G, Eberst L, et al. MEDIPLEX: a phase 1 study of durvalumab (D) combined with pexidartinib (P) in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC) [abstract no. 2579]. J Clin Oncol. 2019;37(Suppl 15):2579.","journal-title":"J Clin Oncol"},{"issue":"Suppl 15","key":"1210_CR26","doi-asserted-by":"publisher","first-page":"10546","DOI":"10.1200\/JCO.2017.35.15_suppl.10546","volume":"35","author":"\/l Hittson","year":"2017","unstructured":"Hittson L, Glod J, Amaya M, et al. Phase I study of pexidartinib (PLX3397) in children with refractory leukemias and solid tumors including neurofibromatosis type I (NF1) related plexiform neurofibromas (PN) [abstract no. 10546]. J Clin Oncol. 2017;35(Suppl 15):10546.","journal-title":"J Clin Oncol"},{"key":"1210_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-019-00745-z","author":"JH Lee","year":"2019","unstructured":"Lee JH, Chen TW, Hsu CH, et al. A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors. Invest New Drugs. 2019. \nhttps:\/\/doi.org\/10.1007\/s10637-019-00745-z\n\n.","journal-title":"Invest New Drugs."},{"key":"1210_CR28","unstructured":"Daiichi Sankyo Company. ENLIVEN phase 3 study of pexidartinib in tenosynovial giant cell tumor (TGCT) will continue to completion following enrollment discontinuation [media release]. 21 Oct 2016. \nhttp:\/\/www.daiichisankyo.com\n\n."},{"key":"1210_CR29","doi-asserted-by":"crossref","unstructured":"Bauer S, Lewis JH, Gelderblom H, et al. Pexidartinib for locally advanced tenosynovial giant cell tumor (TGCT): characterization of hepatic adverse reactions (ARs) [poster no. 1696P]. In: ESMO 2019.","DOI":"10.1093\/annonc\/mdz283.029"},{"issue":"Suppl 15","key":"1210_CR30","doi-asserted-by":"publisher","first-page":"11560","DOI":"10.1200\/JCO.2018.36.15_suppl.11560","volume":"36","author":"M Mastboom","year":"2018","unstructured":"Mastboom M, Palmerini E, Stacchiotti S, et al. First prospective observational study in diffuse-type tenosynovial giant cell tumors [abstract no. 11560]. J Clin Oncol. 2018;36(Suppl 15):11560.","journal-title":"J Clin Oncol"}],"updated-by":[{"DOI":"10.1007\/s40265-020-01280-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T00:00:00Z","timestamp":1582848000000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01210-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-019-01210-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01210-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T23:15:47Z","timestamp":1602198947000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-019-01210-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,10]]},"references-count":30,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["1210"],"URL":"https:\/\/doi.org\/10.1007\/s40265-019-01210-0","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40265-020-01280-5","asserted-by":"object"}]},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,10]]},"assertion":[{"value":"10 October 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2020","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article has been corrected.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2020","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article has been corrected.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. Yvette Lamb is a salaried employee of Adis International Ltd\/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}